{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T05:24:13Z","timestamp":1741411453968,"version":"3.38.0"},"reference-count":31,"publisher":"American Veterinary Medical Association (AVMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["javma"],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec>\n<jats:title>OBJECTIVE<\/jats:title>\n<jats:p>To evaluate whether the administration of 2% dorzolamide ophthalmic solution in dogs undergoing ophthalmic surgery is associated with perianesthetic metabolic acidosis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>ANIMALS<\/jats:title>\n<jats:p>60 dogs, with or without dorzolamide administration, underwent arterial blood gas analysis immediately after anesthesia for ophthalmic surgery between 2019 and 2022; a total of 60 surgeries were evaluated.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>METHODS<\/jats:title>\n<jats:p>This was a retrospective cross-sectional study. Logistic regression analysis was performed to investigate the association between the administration of 2% dorzolamide ophthalmic solution in dogs and the development of metabolic acidosis. Additionally, the influence of various potential risk factors, including age, body weight, sex, use of topical or systemic NSAIDs, and preoperative medications on the occurrence of metabolic acidosis, was evaluated.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>RESULTS<\/jats:title>\n<jats:p>A significant association was found between the use of 2% dorzolamide ophthalmic solution and perianesthetic metabolic acidosis (OR, 6.79; 95% CI, 2.00 to 23.02; <jats:italic>P<\/jats:italic> = .002). Furthermore, topical dorzolamide administration was significantly associated with both perianesthetic hypokalemia (OR, 3.52; 95% CI, 1.11 to 11.20; <jats:italic>P<\/jats:italic> = .033) and perianesthetic hyperchloremia (OR, 9.25; 95% CI, 1.71 to 50.01; <jats:italic>P<\/jats:italic> = .010).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>CLINICAL RELEVANCE<\/jats:title>\n<jats:p>The use of 2% dorzolamide ophthalmic solution is associated with perianesthetic metabolic acidosis, hypokalemia, and hyperchloremia in dogs. It is prudent to be aware of these risks, especially before anesthesia.<\/jats:p>\n<\/jats:sec>","DOI":"10.2460\/javma.23.06.0358","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T18:30:31Z","timestamp":1696617031000},"page":"1-9","source":"Crossref","is-referenced-by-count":0,"title":["Perianesthetic metabolic acidosis is associated with 2% dorzolamide eye drops in dogs that underwent ophthalmic surgery: a retrospective study (2019\u20132022)"],"prefix":"10.2460","volume":"262","author":[{"given":"Jaegook","family":"Lim","sequence":"first","affiliation":[{"name":"Department of Veterinary Clinical Science (Ophthalmology), College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Gwanak-Gu, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inhyung","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinical Sciences (Anesthesiology), College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Gwanak-Gu, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kangmoon","family":"Seo","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinical Science (Ophthalmology), College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Gwanak-Gu, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won-gyun","family":"Son","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinical Sciences (Anesthesiology), College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Gwanak-Gu, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seonmi","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinical Science (Ophthalmology), College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Gwanak-Gu, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1272","reference":[{"issue":"3","key":"ref1","series-title":"Clin Pharmacokinet","first-page":"197","article-title":"Clinical pharmacokinetics of dorzolamide","volume":"41","author":"Martens-Lobenhoffer J","year":"2002","unstructured":"Martens-Lobenhoffer J, Banditt P. Clinical pharmacokinetics of dorzolamide. Clin Pharmacokinet. 2002;41(3):197-205. doi:10.2165\/00003088-200241030-00004"},{"issue":"2","key":"ref2","series-title":"Surv Ophthalmol","first-page":"137","article-title":"Dorzolamide: development and clinical application of a topical carbonic anhydrase inhibitor","volume":"42","author":"Pfeiffer N","year":"1997","unstructured":"Pfeiffer N. Dorzolamide: development and clinical application of a topical carbonic anhydrase inhibitor. Surv Ophthalmol. 1997;42(2):137-151. doi:10.1016\/s0039-6257(97)00053-2"},{"issue":"7","key":"ref3","series-title":"Am J Vet Res","first-page":"1074","article-title":"Effects of ocular administration of ophthalmic 2% dorzolamide hydrochloride solution on aqueous humor flow rate and intraocular pressure in clinically normal cats","volume":"73","author":"Rankin AJ","year":"2012","unstructured":"Rankin AJ, Crumley WR, Allbaugh RA. Effects of ocular administration of ophthalmic 2% dorzolamide hydrochloride solution on aqueous humor flow rate and intraocular pressure in clinically normal cats. Am J Vet Res. 2012;73(7):1074-1078. doi:10.2460\/ajvr.73.7.1074"},{"key":"ref4","series-title":"Veterinary Ophthalmology","first-page":"1173","article-title":"The canine glaucomas","volume":"Vol 1","author":"Plummer CE","year":"2021","unstructured":"Plummer CE, Kom\u00e1romy AM, Gelatt KN. The canine glaucomas. In: Gelatt KN, Ben-Shlomo G, Gilger BC, Hendrix DVH, Kern TJ, Plummer CE, eds. Veterinary Ophthalmology. 6th ed. Vol 1. Wiley Blackwell; 2021:1173-1255."},{"issue":"2","key":"ref5","series-title":"Vet Clin North Am Small Anim Pract","first-page":"357","article-title":"Current concepts in small animal glaucoma: recognition and treatment","volume":"10","author":"Gwin RM","year":"1980","unstructured":"Gwin RM. Current concepts in small animal glaucoma: recognition and treatment. Vet Clin North Am Small Anim Pract. 1980;10(2):357-376. doi:10.1016\/s0195-5616(80)50034-3"},{"issue":"1","key":"ref6","series-title":"Vet Ophthalmol","first-page":"9","article-title":"Advances in topical glaucoma therapy","volume":"5","author":"Willis AM","year":"2002","unstructured":"Willis AM, Diehl KA, Robbin TE. Advances in topical glaucoma therapy. Vet Ophthalmol. 2002;5(1):9-17. doi:10.1046\/j.1463-5216.2001.00202.x"},{"key":"ref7","series-title":"Small Animal Clinical Pharmacology","first-page":"557","article-title":"Ocular clinical pharmacology","author":"Stanley RG","year":"2008","unstructured":"Stanley RG. Ocular clinical pharmacology. In: Maddison JE, Page SW, Church DB, eds. Small Animal Clinical Pharmacology. 2nd ed. W.B. Saunders; 2008:557-573."},{"issue":"6","key":"ref8","series-title":"Drugs Aging","first-page":"477","article-title":"Topical dorzolamide 2%\/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma","volume":"17","author":"Ormrod D","year":"2000","unstructured":"Ormrod D, McClellan K. Topical dorzolamide 2%\/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma. Drugs Aging. 2000;17(6):477-496. doi:10.2165\/00002512-200017060-00005"},{"issue":"6","key":"ref9","series-title":"Am J Vet Res","first-page":"859","article-title":"Effects of topical application of a 2% solution of dorzolamide on intraocular pressure and aqueous humor flow rate in clinically normal dogs","volume":"62","author":"Cawrse MA","year":"2001","unstructured":"Cawrse MA, Ward DA, Hendrix DV. Effects of topical application of a 2% solution of dorzolamide on intraocular pressure and aqueous humor flow rate in clinically normal dogs. Am J Vet Res. 2001;62(6):859-863. doi:10.2460\/ajvr.2001.62.859"},{"issue":"8","key":"ref10","series-title":"Br J Ophthalmol","first-page":"1052","article-title":"Topical dorzolamide and metabolic acidosis in a neonate","volume":"87","author":"Morris S","year":"2003","unstructured":"Morris S, Geh V, Nischal KK, Sahi S, Ahmed MA. Topical dorzolamide and metabolic acidosis in a neonate. Br J Ophthalmol. 2003;87(8):1052-1053. doi:10.1136\/bjo.87.8.1052"},{"issue":"3","key":"ref11","series-title":"J Pediatr Pharmacol Ther","first-page":"256","article-title":"Metabolic acidosis with ophthalmic dorzolamide in a neonate","volume":"21","author":"Capino AC","year":"2016","unstructured":"Capino AC, Dannaway DC, Miller JL. Metabolic acidosis with ophthalmic dorzolamide in a neonate. J Pediatr Pharmacol Ther. 2016;21(3):256-259. doi:10.5863\/1551-6776-21.3.256"},{"issue":"4","key":"ref12","series-title":"Br J Clin Pharmacol","first-page":"796","article-title":"Metabolic acidosis and anaemia associated with dorzolamide in a patient with impaired renal function","volume":"84","author":"Hoffmanov\u00e1 I","year":"2018","unstructured":"Hoffmanov\u00e1 I, S\u00e1nchez D. Metabolic acidosis and anaemia associated with dorzolamide in a patient with impaired renal function. Br J Clin Pharmacol. 2018;84(4):796-799. doi:10.1111\/bcp.13499"},{"key":"ref13","series-title":"Am J Ophthalmol","first-page":"49","article-title":"Risks of topical carbonic anhydrase inhibitors in glaucoma patients with chronic kidney disease: a nationwide population-based study","volume":"253","author":"Wang Y-C","year":"2023","unstructured":"Wang Y-C, Ling XC, Tsai W-H, Liu J-S, Kuo K-L. Risks of topical carbonic anhydrase inhibitors in glaucoma patients with chronic kidney disease: a nationwide population-based study. Am J Ophthalmol. 2023;253:49-55. doi:10.1016\/j.ajo.2023.05.007"},{"issue":"2","key":"ref14","series-title":"Vet Ophthalmol","first-page":"81","article-title":"The feline glaucomas: 82 cases (1995-1999)","volume":"4","author":"Blocker T","year":"2001","unstructured":"Blocker T, Van Der Woerdt A. The feline glaucomas: 82 cases (1995-1999). Vet Ophthalmol. 2001;4(2):81-85. doi:10.1046\/j.1463-5224.2001.00169.x"},{"issue":"6","key":"ref15","series-title":"J Vet Emerg Crit Care (San Antonio)","first-page":"870","article-title":"Hypokalemia and suspected renal tubular acidosis associated with topical carbonic anhydrase inhibitor therapy in a cat","volume":"26","author":"Thiessen CE","year":"2016","unstructured":"Thiessen CE, Tofflemire KL, Makielski KM, Ben-Shlomo G, Whitley RD, Allbaugh RA. Hypokalemia and suspected renal tubular acidosis associated with topical carbonic anhydrase inhibitor therapy in a cat. J Vet Emerg Crit Care (San Antonio). 2016;26(6):870-874. doi:10.1111\/vec.12417"},{"issue":"1","key":"ref16","series-title":"Vet Ophthalmol","first-page":"12","article-title":"Hypokalemia associated with topical administration of dorzolamide 2% ophthalmic solution in cats","volume":"24","author":"Czepiel TM","year":"2021","unstructured":"Czepiel TM, Wasserman NT. Hypokalemia associated with topical administration of dorzolamide 2% ophthalmic solution in cats. Vet Ophthalmol. 2021;24(1):12-19. doi:10.1111\/vop.12773"},{"issue":"6","key":"ref17","series-title":"Vet Anaesth Analg","first-page":"883","article-title":"Metabolic acidosis during general anaesthesia: presumed systemic toxicity caused by topical dorzolamide in a dog","volume":"45","author":"McFadzean WJ","year":"2018","unstructured":"McFadzean WJ, Murrell J, Donaldson D. Metabolic acidosis during general anaesthesia: presumed systemic toxicity caused by topical dorzolamide in a dog. Vet Anaesth Analg. 2018;45(6):883-884. doi:10.1016\/j.vaa.2018.07.001"},{"issue":"5","key":"ref18","series-title":"J Vet Intern Med","first-page":"1107","article-title":"Incidence, nature, and etiology of metabolic acidosis in dogs and cats","volume":"26","author":"Hopper K","year":"2012","unstructured":"Hopper K, Epstein SE. Incidence, nature, and etiology of metabolic acidosis in dogs and cats. J Vet Intern Med. 2012;26(5):1107-1114. doi:10.1111\/j.1939-1676.2012.00983.x"},{"key":"ref19","series-title":"Fluid, Electrolyte, and Acid-Base Disorders in Small Animal Practice","first-page":"231","article-title":"Introduction to acid-base disorders","author":"DiBartola SP","year":"2012","unstructured":"DiBartola SP. Introduction to acid-base disorders. In: Fluid, Electrolyte, and Acid-Base Disorders in Small Animal Practice. 4th ed. Elsevier; 2012:231-252. doi:10.1016\/B978-1-4377-0654-3.00016-0"},{"issue":"1","key":"ref20","series-title":"BMC Vet Res","first-page":"412","article-title":"A cross-sectional study of environmental, dog, and human-related risk factors for positive canine leptospirosis PCR test results in the United States, 2009 to 2016","volume":"15","author":"Smith AM","year":"2019","unstructured":"Smith AM, Arruda AG, Evason MD,  A cross-sectional study of environmental, dog, and human-related risk factors for positive canine leptospirosis PCR test results in the United States, 2009 to 2016. BMC Vet Res. 2019;15(1):412 doi:10.1186\/s12917-019-2148-6"},{"issue":"6","key":"ref21","series-title":"PLoS One","first-page":"e0270313","article-title":"Canine leptospirosis in Canada, test-positive proportion and risk factors (2009 to 2018): a cross-sectional study","volume":"17","author":"Stull JW","year":"2022","unstructured":"Stull JW, Evason M, Weese JS, Yu J, Szlosek D, Smith AM. Canine leptospirosis in Canada, test-positive proportion and risk factors (2009 to 2018): a cross-sectional study. PLoS One. 2022;17(6):e0270313. doi:10.1371\/journal.pone.0270313"},{"key":"ref22","series-title":"Fluid, Electrolyte, and Acid-Base Disorders in Small Animal Practice","first-page":"253","article-title":"Metabolic acid-base disorders","author":"DiBartola SP","year":"2012","unstructured":"DiBartola SP. Metabolic acid-base disorders. In: Fluid, Electrolyte, and Acid-Base Disorders in Small Animal Practice. 4th ed. Elsevier; 2012:253-286. doi:10.1016\/B978-1-4377-0654-3.00017-2"},{"key":"ref23","series-title":"Textbook of Veterinary Internal Medicine","first-page":"592","article-title":"Diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome","author":"O\u2019Brien M","year":"2016","unstructured":"O\u2019Brien M. Diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome. In: Ettinger SJ, Feldman EC, C\u00f4t\u00e9 E, eds. Textbook of Veterinary Internal Medicine. 8th ed. Elsevier Health Sciences; 2016:592-597."},{"issue":"3","key":"ref24","series-title":"J Vet Pharmacol Ther","first-page":"215","article-title":"Some physiological and biochemical effects of acetazolamide in the dog","volume":"2","author":"Rose R","year":"1979","unstructured":"Rose R, Carter J. Some physiological and biochemical effects of acetazolamide in the dog. J Vet Pharmacol Ther. 1979;2(3):215-221. doi:10.1111\/j.1365-2885.1979.tb00378.x"},{"issue":"8","key":"ref25","series-title":"J Am Vet Med Assoc","first-page":"792","article-title":"Effect of acetazolamide in blood acid-base and electrolyte values in dogs","volume":"179","author":"Haskins SC","year":"1981","unstructured":"Haskins SC, Munger RJ, Helphrey MG,  Effect of acetazolamide in blood acid-base and electrolyte values in dogs. J Am Vet Med Assoc. 1981;179(8):792-796."},{"issue":"1-2","key":"ref26","series-title":"Aust Vet J","first-page":"11","article-title":"Severe metabolic acidosis due to acetazolamide intoxication in a dog","volume":"99","author":"Johnston L","year":"2021","unstructured":"Johnston L, Leister E, Singer L. Severe metabolic acidosis due to acetazolamide intoxication in a dog. Aust Vet J. 2021;99(1-2):11-14. doi:10.1111\/avj.13027"},{"issue":"1","key":"ref27","series-title":"J Gerontol A Biol Sci Med Sci","first-page":"B91","article-title":"Age and systemic acid-base equilibrium: analysis of published data","volume":"51","author":"Frassetto L","year":"1996","unstructured":"Frassetto L, Sebastian A. Age and systemic acid-base equilibrium: analysis of published data. J Gerontol A Biol Sci Med Sci. 1996;51(1):B91-B99. doi:10.1093\/gerona\/51a.1.b91"},{"key":"ref28","series-title":"Textbook of Veterinary Internal Medicine","first-page":"531","article-title":"Acid-base, oximetry, and blood gas analysis","author":"Kerl ME","year":"2016","unstructured":"Kerl ME. Acid-base, oximetry, and blood gas analysis. In: Ettinger SJ, Feldman EC, C\u00f4t\u00e9 E, eds. Textbook of Veterinary Internal Medicine. 8th ed. Elsevier Health Sciences; 2016:531-535."},{"issue":"6","key":"ref29","series-title":"Anesthesiology","first-page":"1445","article-title":"Hyperventilation in the treatment of metabolic acidosis does not adversely affect pulmonary gas exchange","volume":"81","author":"Domino KB","year":"1994","unstructured":"Domino KB, Hlastala MP. Hyperventilation in the treatment of metabolic acidosis does not adversely affect pulmonary gas exchange. Anesthesiology. 1994;81(6):1445-1453. doi:10.1097\/00000542-199412000-00020"},{"issue":"5","key":"ref30","series-title":"Eur J Clin Pharmacol","first-page":"455","article-title":"Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide","volume":"47","author":"Biollaz J","year":"1995","unstructured":"Biollaz J, Munafo A, Buclin T,  Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide. Eur J Clin Pharmacol. 1995;47(5):455-460. doi:10.1007\/BF00196861"},{"issue":"1","key":"ref31","series-title":"Ophthalmology","first-page":"88","article-title":"Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation","volume":"105","author":"Rosenberg LF","year":"1998","unstructured":"Rosenberg LF, Krupin T, Tang L-Q, Hong PH, Ruderman JM. Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation. Ophthalmology. 1998;105(1):88-92. doi:10.1016\/s0161-6420(98)91421-x"}],"container-title":["Journal of the American Veterinary Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/262\/2\/javma.23.06.0358.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/262\/2\/javma.23.06.0358.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/262\/2\/javma.23.06.0358.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T13:05:53Z","timestamp":1741352753000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/262\/2\/javma.23.06.0358.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":31,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.2460\/javma.23.06.0358","relation":{},"ISSN":["0003-1488"],"issn-type":[{"type":"print","value":"0003-1488"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}